Merck & Co. Inc.

07/27/2021 | Press release | Distributed by Public on 07/27/2021 04:51

Merck Announces Phase 3 KEYNOTE-355 Trial Met Primary Endpoint of Overall Survival (OS) in Patients with Metastatic Triple-Negative Breast Cancer Whose Tumors Expressed PD-L1[...]